Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adjuvant therapy for colon cancer

J S Macdonald1

  • 1Temple University Cancer Center in Philadelphia, Pennsylvania, USA.

CA: a Cancer Journal for Clinicians
|July 1, 1997
PubMed
Summary

Adjuvant therapy for stage III colon cancer, particularly 5-FU/levamisole, is a cost-effective standard of care. While clinical trials are preferred, established regimens improve survival for resected colon cancer patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

An assessment of the carcinogenic potential of ezetimibe using nonclinical data in a weight-of-evidence approach.

Toxicology·2009
Same author

Home from home: residents' opinions of nursing homes and long-stay wards.

Age and ageing·2005
Same author

Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2003
Same author

Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study.

Annals of oncology : official journal of the European Society for Medical Oncology·2002
Same author

Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2002

Area of Science:

  • Oncology
  • Gastroenterology
  • Clinical Therapeutics

Background:

  • Adjuvant therapy is a standard for resected colon cancer, especially Stage III.
  • 5-FU/levamisole therapy for Stage III colon cancer is highly cost-effective, saving a year of life for under $5,000.
  • Current treatments improve survival but are not perfect, highlighting the need for ongoing research and clinical trials.

Purpose of the Study:

  • To review current adjuvant therapy options for colon cancer.
  • To discuss the efficacy and cost-effectiveness of different treatment regimens.
  • To explore the potential benefits of adjuvant therapy in earlier stages and high-risk patient groups.

Main Methods:

  • Review of existing clinical data and guidelines for colon cancer adjuvant therapy.
  • Analysis of cost-effectiveness data for 5-FU/levamisole therapy.
  • Discussion of various 5-FU-based regimens and their durations (6-12 months).

Main Results:

  • 5-FU-based regimens significantly increase overall and disease-free survival in Stage III colon cancer.
  • 5-FU plus levamisole for 12 months is comparable in efficacy to shorter 5-FU/leucovorin regimens.
  • 5-FU/levamisole may offer advantages in terms of reduced toxicity compared to 5-FU/leucovorin.

Conclusions:

  • Adjuvant therapy is a critical component of colon cancer care, particularly for Stage III.
  • While 5-FU/levamisole is a viable option, participation in clinical trials is encouraged.
  • Further research into molecular factors may refine adjuvant therapy selection for Stage II patients.

Related Experiment Videos